Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 600 shares, a drop of 93.0% from the June 30th total of 8,600 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average trading volume of 5,500 shares, the days-to-cover ratio is presently 0.1 days.

Xenetic Biosciences Stock Down 3.6 %

Xenetic Biosciences stock traded down $0.15 during midday trading on Thursday, hitting $4.02. 10,885 shares of the stock were exchanged, compared to its average volume of 5,788. The company has a fifty day simple moving average of $3.98 and a two-hundred day simple moving average of $3.95. Xenetic Biosciences has a 52 week low of $2.87 and a 52 week high of $5.97. The stock has a market capitalization of $6.19 million, a PE ratio of -1.42 and a beta of 2.28.

Xenetic Biosciences (NASDAQ:XBIO) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.01. Xenetic Biosciences had a negative net margin of 182.99% and a negative return on equity of 43.40%. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.65 million. As a group, equities research analysts anticipate that Xenetic Biosciences will post -0.96 EPS for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.